Results from Lilly's Landmark Phase 3 Trial of Donanemab Presented at Alzheimer's Association Conference and Published in JAMA

Eli Lilly and Company (NYSE: LLY) presented full results from the Phase 3 TRAILBLAZER-ALZ 2 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's disease (AD). The data were shared at the 2023 Alzheimer's Association International Conference ...

Related Keywords

United States ,China ,American ,Eli Lilly ,Mark Mintun ,Anne White ,Linkedin ,Donanemab Group ,Neuroscience Research Development ,Indiana University School Of Medicine ,Instagram ,Facebook ,Association International Conference ,Twitter ,Placebo Group ,Alzheimer Disease Center ,Journal Of The American Medical Association ,American Medical Association ,Disease Rating Scale ,Clinical Dementia Rating Sum ,Liana Apostolova ,Indiana University School ,Neuroscience Research ,Association International ,New England Journal ,Clinical Trials ,